Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data

Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study

Living donor liver transplantation for hepatocellular carcinoma using expanded criteria and alpha-fetoprotein threshold of 1000 ng/mL

Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria

The clinical value of "Hangzhou Criteria" in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of 1163 cases on a multi-center basis

Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.

Expanded Criterion for Hepatocellular Carcinoma in Liver Transplantation

Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria

Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-center experience

Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients with Hepatocellular Carcinoma Awaiting a Liver Transplant.

Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference

The Stratifying Value of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma.

Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy

Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria

Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West–East Collaborative Effort

Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma: What Are the Optimal Criteria?